<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612909</url>
  </required_header>
  <id_info>
    <org_study_id>IVACFLU-A/H5N1-0203</org_study_id>
    <nct_id>NCT02612909</nct_id>
    <nct_alias>NCT02815098</nct_alias>
  </id_info>
  <brief_title>A Safety and Immunogenicity Study of IVACFLU-A/H5N1</brief_title>
  <official_title>A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Vaccines and Medical Biologicals, Vietnam</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Hygiene and Epidemiology, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Vaccines and Medical Biologicals, Vietnam</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis was that two 0.5 mL doses of whole virion monovalent A/H5N1 influenza
      vaccine (IVACFLU-A/H5N1) adjuvanted with alum would be safe and well tolerated in healthy
      adults, and that at least one of the two doses tested would be immunogenic in 60% or more of
      the subjects tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the A/H1N1 (2009) pandemic has subsided and the virus has become endemic, the threat
      of another pandemic due to avian influenza A/H5N1 remains constant. Since 1997, highly
      pathogenic A/H5N1 avian viruses have caused both widespread outbreaks in poultry with high
      mortality and sporadic, severe, and fatal disease in humans. Southeast Asian countries,
      including Vietnam, have been affected by influenza A/H5N1. From 2003 through March 2015, WHO
      has reported 826 confirmed human cases of A/H5N1 influenza infection; including 440 fatal
      cases (World Health Organization, 2015). Southeast Asian countries accounted for 42% of all
      confirmed influenza A/H5N1 cases reported since 2003, and influenza A/H5N1 infection in
      animals is now thought to be endemic in the region (World Health Organization, 2015). As of
      March 2015, Vietnam has reported 127 confirmed human cases and 64 deaths. In 2014, two cases
      of A/H5N1 avian influenza were reported in Vietnam. Therefore, the risk of transmission to
      human is still present.

      At the time of the study, no influenza A/H5N1 vaccine had been licensed in Vietnam.
      IVACFLU-A/H5N1 is an influenza A/H5N1 vaccine produced by Institute of Vaccines and Medical
      Biologicals (IVAC) using embryonated chicken eggs. IVACFLU-A/H5N1 is a whole virus vaccine,
      collected in a linear sucrose density gradient solution using a continuous flow centrifuge
      (Alfa Wassermann, West Caldwell, NJ) and inactivated with formaldehyde. The vaccine is alum
      adjuvanted. Vaccine strain NIBRG-14 derived from original influenza A/Vietnam/1194/2004 was
      provided to IVAC by the National Institute for Biological Standards and Control of the Health
      Protection Agency of the United Kingdom. A clinical trial of IVACFLU-A/H5N1 vaccine conducted
      in 75 subjects at the Ben Luc Health District in Vietnam in 2014 showed that the vaccine is
      safe and immunogenic at doses of 7.5 and 15 mcg.

      This study was conducted in two stages: Phase 2 was a dose selection study where subjects
      were randomized to one of the three groups (15 mcg IVACFLU-A/H5N1 vaccine, 30 mcg
      IVACFLU-A/H5N1 vaccine or placebo) at a 1:1:1 ratio. The conduct of Phase 3 was dependent on
      showing hemagglutination inhibition (HAI) response titer of ≥1:40 in ≥60% of vaccine
      recipients in at least one of the two Phase 2 IVACFLU-A/H5N1 vaccine groups. Based on the
      review of immunogenicity and safety results from the Phase 2 study, a dose of study vaccine
      was selected for Phase 3. Subjects were randomized at two sites (Khanh Hoa and Hai Phong) to
      receive the IVACFLU-A/H5N1 vaccine dose selected in Phase 2 or placebo . Safety was assessed
      in all subjects and immunogenicity was measured in a subset of subjects at the Hai Phong
      study site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Actual">August 30, 2017</completion_date>
  <primary_completion_date type="Actual">August 29, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40</measure>
    <time_frame>Day 1, Day 43</time_frame>
    <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer</measure>
    <time_frame>Day 22, Day 43</time_frame>
    <description>Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer</measure>
    <time_frame>Day 43</time_frame>
    <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer</measure>
    <time_frame>Day 1, Day 22, Day 43</time_frame>
    <description>Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer</measure>
    <time_frame>Day 1, Day 43</time_frame>
    <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1</measure>
    <time_frame>Day 22, Day 43</time_frame>
    <description>Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1</measure>
    <time_frame>Day 43</time_frame>
    <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects Experiencing Reactogenicity</measure>
    <time_frame>30 minutes after each injection</time_frame>
    <description>Immediate reactogenicity (30 minutes post-injection) were evaluated on Day 1 and Day 22 and consisted of:
Inspection of the upper arms for the presence or absence of redness, swelling, hardness, pain, or tenderness; and
Documentation of the presence or absence of headache, fever, fatigue/malaise, muscle aches, joint aches, nausea, vomiting, or chills.
Immediate reactogenicity were assessed by a study physician or appropriately trained medical staff.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects Experiencing Reactogenicity</measure>
    <time_frame>7 days after each vaccination</time_frame>
    <description>Reported solicited signs and symptoms were recorded by the subject on the Diary Card from Days 1-7 and Days 22-28 in the study, then evaluated by study physician on Days 8, 22, and 29.The evaluated solicited local reactogenicity events were as follows:
Size of redness (at site of injection) in centimeters (cm)
Size of swelling (at site of injection) in cm
Size of induration (hardness at site of injection) in cm
Pain (at site of injection)
Tenderness (at site of injection)
The evaluated solicited systemic reactogenicity events were as follows:
Fever/body temperature (and body location of measurement)
Fatigue/malaise
Generalized muscle aches
Joint aches/pains
Chills
Nausea
Vomiting
Headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects Experiencing Unsolicited Adverse Events (AE)</measure>
    <time_frame>21 days after each vaccination</time_frame>
    <description>Unsolicited AEs were any AEs that occurred any time after study product was given (temporally related to study product), whether or not deemed &quot;related&quot; to the product, and were not solicited. Unsolicited AEs were either observed by study staff while the subject was at a clinic for a study visit or reported by the subject at any time. Any solicited sign or symptom starting after 7 days post-study product injection was recorded as an &quot;unsolicited AE&quot;.
For the Phase 2 study, laboratory results were considered AEs when the result was Grade 2 or above.
Any medical condition that was present at the time that the subject was enrolled was not reported as an AE, but was reported as a pre-existing condition on the Medical History Form. However, if this condition occurred with greater frequency or severity during the study, it was recorded as an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Subjects Experiencing Unsolicited Serious Adverse Events (SAE)</measure>
    <time_frame>90 days</time_frame>
    <description>Defined as an adverse event that led to death, was life-threatening (subject at immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in congenital anomaly/birth defect; resulted in a persistent or significant disability or incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer</measure>
    <time_frame>Day 22, Day 43</time_frame>
    <description>The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer</measure>
    <time_frame>Day 43</time_frame>
    <description>The MN assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.
In Phase 3, MN assay was conducted in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in order to have at least 200 evaluable subjects receiving IVACFLU A/H5N1 and 40 evaluable subjects receiving placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Geometric Mean Neutralizing Antibody Titer</measure>
    <time_frame>Day 1, Day 22, Day 43</time_frame>
    <description>The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Geometric Mean Neutralizing Antibody Titer</measure>
    <time_frame>Day 1, Day 43</time_frame>
    <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1</measure>
    <time_frame>Day 22, Day 43</time_frame>
    <description>The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1</measure>
    <time_frame>Day 43</time_frame>
    <description>The MN assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.
In Phase 3, MN assay was conducted in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in order to have at least 200 evaluable subjects receiving IVACFLU A/H5N1 and 40 evaluable subjects receiving placebo.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">930</enrollment>
  <condition>Avian Influenza</condition>
  <arm_group>
    <arm_group_label>Phase 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Vaccine (15 mcg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Vaccine (30 mcg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3: Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IVACFLU-A/H5N1 vaccine</intervention_name>
    <description>Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.</description>
    <arm_group_label>Phase 2: Vaccine (15 mcg)</arm_group_label>
    <arm_group_label>Phase 2: Vaccine (30 mcg)</arm_group_label>
    <arm_group_label>Phase 3: Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.</description>
    <arm_group_label>Phase 2: Placebo</arm_group_label>
    <arm_group_label>Phase 3: Placebo</arm_group_label>
    <other_name>Sterile Phosphate Buffered Saline (PBS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adult 18 through 60 years of age at the enrollment visit.

          -  Literate (by self-report) and willing to provide written informed consent.

          -  Healthy adults, as established by the medical history and screening evaluations,
             including physical examination, capable and willing to complete Diary Cards, and
             willing to return for all follow-up visits.

          -  For females able to become pregnant, willing to utilize reliable birth control
             measures (intrauterine device, hormonal contraception, condoms) through the Day 43
             visit.

        Exclusion Criteria:

          -  Participation in another clinical trial involving any vaccine or therapy within the
             previous three months, or planned enrollment in such a trial during the period of this
             study.

          -  Received any non-study vaccine within 4 weeks prior to enrollment or refused to
             postpone receipt of such vaccines until after the Day 43 visit.

          -  Current or recent (within 2 weeks of enrollment) acute illness with or without fever.

          -  Received immune globulin or other blood products within 3 months prior to study
             enrollment or planned receipt of such products prior to the Day 43 visit.

          -  Chronic administration (defined as more than 14 consecutively-prescribed days) of
             immunosuppressants or other immune-modulating therapy within six months prior to study
             enrollment. (For corticosteroids, this meant prednisone or equivalent, 0.5 mg per kg
             per day; topical or intranasal steroids were allowed.)

          -  History of asthma.

          -  Hypersensitivity after previous administration of any vaccine.

          -  Suspected or known hypersensitivity to any of the study vaccine components, including
             chicken or egg protein, antibiotics, and rubber (from the vaccine vial stoppers).

          -  Acute or chronic clinically significant pulmonary, cardiovascular, hepatobiliary,
             metabolic, neurologic, psychiatric, or renal functional abnormality, as determined by
             medical history, physical examination, or clinical laboratory screening tests (Phase 2
             only), which in the opinion of the investigator, might have interfered with the study
             objectives.

          -  History of any blood or solid organ cancer.

          -  History of thrombocytopenic purpura or known bleeding disorder.

          -  History of seizures.

          -  Known or suspected immunosuppressed or immune deficient condition of any kind.

          -  Known Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection by self-report
             (Phase 3) or a positive test for either HBV surface antigen (HBsAg) or HCV antibody
             using anti-HCV test (Phase 2).

          -  Known HIV infection (self-report)

          -  Known active tuberculosis or symptoms of active tuberculosis (self-report).

          -  History of chronic alcohol abuse and/or illegal drug use.

          -  Pregnancy or lactation (a negative pregnancy test was required before administration
             of study product for all women of childbearing potential).

          -  History of Guillain-Barre Syndrome.

          -  Any condition in the opinion of the investigator that would have increased the health
             risk of the subject if he/she participated in the study or interfered with the
             evaluation of the study objectives.

        Note: Minor out-of-range laboratory values no greater than Grade 1 were not considered to
        be exclusionary at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tran N Duong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Hygiene and Epidemiology, Vietnam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phase 3: Hai Phong Provincial Preventive Medicine Center</name>
      <address>
        <city>Haiphong</city>
        <state>Hai Phong</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phase 2 &amp; 3: Khanh Hoa Provincial Health Department</name>
      <address>
        <city>Nha Trang</city>
        <state>Khanh Hoa</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <results_first_submitted>January 17, 2019</results_first_submitted>
  <results_first_submitted_qc>January 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>May 12, 2019</last_update_submitted>
  <last_update_submitted_qc>May 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avian Influenza</keyword>
  <keyword>A/H5N1 vaccine</keyword>
  <keyword>IVAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 22, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02612909/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 24, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02612909/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase 2 &amp; 3: Recruitment occurred from communes affiliated with the District Health Centers. Commune health workers identified potential participants through home visits and invited interested people to attend an information session. People heard about the study and those interested had individual consent for screening.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 2: Placebo</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="P2">
          <title>Phase 2: Vaccine (15 mcg)</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="P3">
          <title>Phase 2: Vaccine (30 mcg)</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="P4">
          <title>Phase 3: Placebo</title>
          <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="P5">
          <title>Phase 3: Vaccine</title>
          <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Injection 1</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Injection 2</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Day 29 Clinic Visit</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Day 43 Clinic Visit</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="105"/>
                <participants group_id="P5" count="525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Injection 1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="105"/>
                <participants group_id="P5" count="525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Injection 2</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="103"/>
                <participants group_id="P5" count="520"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Day 29 Clinic Visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Day 43 Clinic Visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="524"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 2: Placebo</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="B2">
          <title>Phase 2: Vaccine (15 mcg)</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="B3">
          <title>Phase 2: Vaccine (30 mcg)</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="B4">
          <title>Phase 3: Placebo</title>
          <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="B5">
          <title>Phase 3: Vaccine</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="105"/>
            <count group_id="B5" value="525"/>
            <count group_id="B6" value="930"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="9.62"/>
                    <measurement group_id="B2" value="39.8" spread="9.99"/>
                    <measurement group_id="B3" value="39.7" spread="9.63"/>
                    <measurement group_id="B4" value="39.9" spread="9.61"/>
                    <measurement group_id="B5" value="40.2" spread="9.72"/>
                    <measurement group_id="B6" value="40.0" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="286"/>
                    <measurement group_id="B6" value="550"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="239"/>
                    <measurement group_id="B6" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Kinh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="524"/>
                    <measurement group_id="B6" value="929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40</title>
        <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
        <time_frame>Day 1, Day 43</time_frame>
        <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O5">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40</title>
          <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
          <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40</title>
        <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
        <time_frame>Day 1, Day 22</time_frame>
        <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40</title>
          <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
          <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer</title>
        <description>Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
        <time_frame>Day 22, Day 43</time_frame>
        <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer</title>
          <description>Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
          <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer</title>
        <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
        <time_frame>Day 43</time_frame>
        <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer</title>
          <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
          <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer</title>
        <description>Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
        <time_frame>Day 1, Day 22, Day 43</time_frame>
        <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer</title>
          <description>Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
          <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" lower_limit="5.23" upper_limit="5.74"/>
                    <measurement group_id="O2" value="5.62" lower_limit="5.34" upper_limit="5.91"/>
                    <measurement group_id="O3" value="5.68" lower_limit="5.30" upper_limit="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" lower_limit="5.26" upper_limit="5.80"/>
                    <measurement group_id="O2" value="31.67" lower_limit="24.60" upper_limit="40.77"/>
                    <measurement group_id="O3" value="42.16" lower_limit="33.45" upper_limit="53.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.63" lower_limit="5.31" upper_limit="5.96"/>
                    <measurement group_id="O2" value="62.65" lower_limit="52.10" upper_limit="75.34"/>
                    <measurement group_id="O3" value="59.20" lower_limit="49.87" upper_limit="70.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer</title>
        <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
        <time_frame>Day 1, Day 43</time_frame>
        <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer</title>
          <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
          <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" lower_limit="4.96" upper_limit="5.11"/>
                    <measurement group_id="O2" value="5.08" lower_limit="4.97" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.20" lower_limit="5.06" upper_limit="5.34"/>
                    <measurement group_id="O2" value="27.61" lower_limit="24.38" upper_limit="31.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1</title>
        <description>Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
        <time_frame>Day 22, Day 43</time_frame>
        <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1</title>
          <description>Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
          <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.99" upper_limit="1.02"/>
                    <measurement group_id="O2" value="5.64" lower_limit="4.43" upper_limit="7.18"/>
                    <measurement group_id="O3" value="7.42" lower_limit="5.93" upper_limit="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="1.00" upper_limit="1.05"/>
                    <measurement group_id="O2" value="11.15" lower_limit="9.35" upper_limit="13.29"/>
                    <measurement group_id="O3" value="10.41" lower_limit="8.79" upper_limit="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1</title>
        <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
        <time_frame>Day 43</time_frame>
        <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1</title>
          <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
          <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.99" upper_limit="1.02"/>
                    <measurement group_id="O2" value="5.31" lower_limit="4.69" upper_limit="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects Experiencing Reactogenicity</title>
        <description>Immediate reactogenicity (30 minutes post-injection) were evaluated on Day 1 and Day 22 and consisted of:
Inspection of the upper arms for the presence or absence of redness, swelling, hardness, pain, or tenderness; and
Documentation of the presence or absence of headache, fever, fatigue/malaise, muscle aches, joint aches, nausea, vomiting, or chills.
Immediate reactogenicity were assessed by a study physician or appropriately trained medical staff.</description>
        <time_frame>30 minutes after each injection</time_frame>
        <population>Subjects who received injections</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O5">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects Experiencing Reactogenicity</title>
          <description>Immediate reactogenicity (30 minutes post-injection) were evaluated on Day 1 and Day 22 and consisted of:
Inspection of the upper arms for the presence or absence of redness, swelling, hardness, pain, or tenderness; and
Documentation of the presence or absence of headache, fever, fatigue/malaise, muscle aches, joint aches, nausea, vomiting, or chills.
Immediate reactogenicity were assessed by a study physician or appropriately trained medical staff.</description>
          <population>Subjects who received injections</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection 1: any local reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1: any systemic reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2: any local reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2: any systemic reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects Experiencing Reactogenicity</title>
        <description>Reported solicited signs and symptoms were recorded by the subject on the Diary Card from Days 1-7 and Days 22-28 in the study, then evaluated by study physician on Days 8, 22, and 29.The evaluated solicited local reactogenicity events were as follows:
Size of redness (at site of injection) in centimeters (cm)
Size of swelling (at site of injection) in cm
Size of induration (hardness at site of injection) in cm
Pain (at site of injection)
Tenderness (at site of injection)
The evaluated solicited systemic reactogenicity events were as follows:
Fever/body temperature (and body location of measurement)
Fatigue/malaise
Generalized muscle aches
Joint aches/pains
Chills
Nausea
Vomiting
Headache</description>
        <time_frame>7 days after each vaccination</time_frame>
        <population>Subjects who received injections</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O5">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects Experiencing Reactogenicity</title>
          <description>Reported solicited signs and symptoms were recorded by the subject on the Diary Card from Days 1-7 and Days 22-28 in the study, then evaluated by study physician on Days 8, 22, and 29.The evaluated solicited local reactogenicity events were as follows:
Size of redness (at site of injection) in centimeters (cm)
Size of swelling (at site of injection) in cm
Size of induration (hardness at site of injection) in cm
Pain (at site of injection)
Tenderness (at site of injection)
The evaluated solicited systemic reactogenicity events were as follows:
Fever/body temperature (and body location of measurement)
Fatigue/malaise
Generalized muscle aches
Joint aches/pains
Chills
Nausea
Vomiting
Headache</description>
          <population>Subjects who received injections</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection 1: any local reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1: any systemic reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2: any local reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="520"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2: any systemic reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="520"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects Experiencing Unsolicited Adverse Events (AE)</title>
        <description>Unsolicited AEs were any AEs that occurred any time after study product was given (temporally related to study product), whether or not deemed &quot;related&quot; to the product, and were not solicited. Unsolicited AEs were either observed by study staff while the subject was at a clinic for a study visit or reported by the subject at any time. Any solicited sign or symptom starting after 7 days post-study product injection was recorded as an &quot;unsolicited AE&quot;.
For the Phase 2 study, laboratory results were considered AEs when the result was Grade 2 or above.
Any medical condition that was present at the time that the subject was enrolled was not reported as an AE, but was reported as a pre-existing condition on the Medical History Form. However, if this condition occurred with greater frequency or severity during the study, it was recorded as an AE.</description>
        <time_frame>21 days after each vaccination</time_frame>
        <population>Subjects who received injections</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O5">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects Experiencing Unsolicited Adverse Events (AE)</title>
          <description>Unsolicited AEs were any AEs that occurred any time after study product was given (temporally related to study product), whether or not deemed &quot;related&quot; to the product, and were not solicited. Unsolicited AEs were either observed by study staff while the subject was at a clinic for a study visit or reported by the subject at any time. Any solicited sign or symptom starting after 7 days post-study product injection was recorded as an &quot;unsolicited AE&quot;.
For the Phase 2 study, laboratory results were considered AEs when the result was Grade 2 or above.
Any medical condition that was present at the time that the subject was enrolled was not reported as an AE, but was reported as a pre-existing condition on the Medical History Form. However, if this condition occurred with greater frequency or severity during the study, it was recorded as an AE.</description>
          <population>Subjects who received injections</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection 1: at least one AE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1: at least 1 severe AE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1: at least 1 treatment-related AE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="105"/>
                    <count group_id="O5" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2: at least one AE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="520"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2: at least 1 severe AE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="520"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2: at least 1 treatment-related AE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="520"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Subjects Experiencing Unsolicited Serious Adverse Events (SAE)</title>
        <description>Defined as an adverse event that led to death, was life-threatening (subject at immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in congenital anomaly/birth defect; resulted in a persistent or significant disability or incapacity.</description>
        <time_frame>90 days</time_frame>
        <population>Subjects who received injections</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O5">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects Experiencing Unsolicited Serious Adverse Events (SAE)</title>
          <description>Defined as an adverse event that led to death, was life-threatening (subject at immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in congenital anomaly/birth defect; resulted in a persistent or significant disability or incapacity.</description>
          <population>Subjects who received injections</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer</title>
        <description>The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.</description>
        <time_frame>Day 22, Day 43</time_frame>
        <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer</title>
          <description>The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.</description>
          <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer</title>
        <description>The MN assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.
In Phase 3, MN assay was conducted in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in order to have at least 200 evaluable subjects receiving IVACFLU A/H5N1 and 40 evaluable subjects receiving placebo.</description>
        <time_frame>Day 43</time_frame>
        <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer</title>
          <description>The MN assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.
In Phase 3, MN assay was conducted in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in order to have at least 200 evaluable subjects receiving IVACFLU A/H5N1 and 40 evaluable subjects receiving placebo.</description>
          <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Geometric Mean Neutralizing Antibody Titer</title>
        <description>The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.</description>
        <time_frame>Day 1, Day 22, Day 43</time_frame>
        <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Geometric Mean Neutralizing Antibody Titer</title>
          <description>The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.</description>
          <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.15" lower_limit="7.03" upper_limit="7.26"/>
                    <measurement group_id="O2" value="7.10" lower_limit="7.04" upper_limit="7.15"/>
                    <measurement group_id="O3" value="7.19" lower_limit="7.07" upper_limit="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.12" lower_limit="7.02" upper_limit="7.22"/>
                    <measurement group_id="O2" value="13.78" lower_limit="11.23" upper_limit="16.92"/>
                    <measurement group_id="O3" value="29.76" lower_limit="24.47" upper_limit="36.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.12" lower_limit="7.02" upper_limit="7.22"/>
                    <measurement group_id="O2" value="29.76" lower_limit="24.47" upper_limit="36.20"/>
                    <measurement group_id="O3" value="28.48" lower_limit="24.34" upper_limit="33.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3: Geometric Mean Neutralizing Antibody Titer</title>
        <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
        <time_frame>Day 1, Day 43</time_frame>
        <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3: Geometric Mean Neutralizing Antibody Titer</title>
          <description>Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.</description>
          <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.07" lower_limit="7.07" upper_limit="7.07"/>
                    <measurement group_id="O2" value="7.07" lower_limit="7.07" upper_limit="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.07" lower_limit="7.07" upper_limit="7.07"/>
                    <measurement group_id="O2" value="26.16" lower_limit="22.66" upper_limit="30.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1</title>
        <description>The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.</description>
        <time_frame>Day 22, Day 43</time_frame>
        <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Placebo</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Vaccine (15 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2: Vaccine (30 mcg)</title>
            <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1</title>
          <description>The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.</description>
          <population>Subjects who received the prior injections (as applicable) and had valid sera samples for the day measured</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.99" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.94" lower_limit="1.59" upper_limit="2.38"/>
                    <measurement group_id="O3" value="2.02" lower_limit="1.67" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.99" upper_limit="1.00"/>
                    <measurement group_id="O2" value="4.19" lower_limit="3.46" upper_limit="5.09"/>
                    <measurement group_id="O3" value="3.96" lower_limit="3.38" upper_limit="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1</title>
        <description>The MN assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.
In Phase 3, MN assay was conducted in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in order to have at least 200 evaluable subjects receiving IVACFLU A/H5N1 and 40 evaluable subjects receiving placebo.</description>
        <time_frame>Day 43</time_frame>
        <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Placebo</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Vaccine</title>
            <description>Subjects participating in Phase 3 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1</title>
          <description>The MN assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.
In Phase 3, MN assay was conducted in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in order to have at least 200 evaluable subjects receiving IVACFLU A/H5N1 and 40 evaluable subjects receiving placebo.</description>
          <population>Subjects who received 2 injections and had valid sera samples for the day measured</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="3.70" lower_limit="3.21" upper_limit="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days for non-serious adverse events, 90 days for serious adverse events</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase 2: Placebo</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="E2">
          <title>Phase 2: Vaccine (15 mcg)</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="E3">
          <title>Phase 2: Vaccine (30 mcg)</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="E4">
          <title>Phase 3: Placebo</title>
          <description>Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
        <group group_id="E5">
          <title>Phase 3: Vaccine</title>
          <description>Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesion</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Abdominal symptom</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral fever</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Refraction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Periodontal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Abdominal symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sebaceous gland infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Abdominal adhesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Le Van Be</name_or_title>
      <organization>IVAC</organization>
      <phone>(+84 90) 3501529</phone>
      <email>ivaclevabe@dng.vnn.vn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

